{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T17:02:11Z","timestamp":1763226131479,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000967","name":"American Health Assistance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000967","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.biopsych.2013.11.019","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T03:42:03Z","timestamp":1385610123000},"page":"553-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Alzheimer\u2019s Disease: New Data Highlight Nonneuronal Cell Types and the Necessity for Presymptomatic Prevention Strategies"],"prefix":"10.1016","volume":"75","author":[{"given":"Sam","family":"Gandy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2013.11.019_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2013.11.019_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev-med-092611-084441","article-title":"Toward the treatment and prevention of Alzheimer\u2019s disease: Rational strategies and recent progress","volume":"64","author":"Gandy","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biopsych.2013.11.019_bib3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2013.11.019_bib4","unstructured":"Gandy S, Ikonomovic MD, Mitsis E, Elder G, Ahlers ST, Barth J, et al. (in press): Chronic traumatic encephalopathy. Molecular Neurodegen."},{"key":"10.1016\/j.biopsych.2013.11.019_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.autrev.2008.03.007","article-title":"Natural human antibodies to amyloid beta peptide","volume":"7","author":"Szabo","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.biopsych.2013.11.019_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-2094-10-5","article-title":"Mechanisms of action of naturally occurring antibodies against \u03b2-amyloid on microglia","volume":"10","author":"Gold","year":"2013","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.biopsych.2013.11.019_bib7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1302513","article-title":"Regulatory innovation and drug development for early-stage Alzheimer\u2019s disease","volume":"368","author":"Kozauer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2013.11.019_bib8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.biopsych.2012.08.015","article-title":"Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype","volume":"73","author":"Thambisetty","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.11.019_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biopsych.2013.01.013","article-title":"CR1 and the \u201cvanishing amyloid\u201d hypothesis of Alzheimer\u2019s disease","volume":"73","author":"Gandy","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2013.11.019_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S1740925X08000136","article-title":"The effects of aging, injury and disease on microglial function: A case for cellular senescence","volume":"3","author":"Miller","year":"2007","journal-title":"Neuron Glia Biol"},{"key":"10.1016\/j.biopsych.2013.11.019_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2013.11.019_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer\u2019s disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2013.11.019_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2013.03.030","article-title":"Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer\u2019s disease","volume":"153","author":"Zhang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2013.11.019_bib14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nn.2432","article-title":"Formation and maintenance of Alzheimer\u2019s disease beta-amyloid plaques in the absence of microglia","volume":"12","author":"Grathwohl","year":"2009","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2013.11.019_bib15","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/nm.2965","article-title":"Inhibition of IL-12\/IL-23 signaling reduces Alzheimer\u2019s disease-like pathology and cognitive decline","volume":"18","author":"vom Berg","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2013.11.019_bib16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1523\/JNEUROSCI.3268-10.2011","article-title":"CD45 deficiency drives amyloid-\u03b2 peptide oligomers and neuronal loss in Alzheimer\u2019s disease mice","volume":"31","author":"Zhu","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.11.019_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ajhg.2008.10.008","article-title":"Genome-wide association analysis reveals putative Alzheimer\u2019s disease susceptibility loci in addition to APOE","volume":"83","author":"Bertram","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.biopsych.2013.11.019_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer\u2019s disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.biopsych.2013.11.019_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuron.2013.04.014","article-title":"Alzheimer\u2019s disease risk gene CD33 inhibits microglial uptake of amyloid beta","volume":"78","author":"Griciuc","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2013.11.019_bib20","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2013.11.019_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002648","article-title":"Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease","volume":"3","author":"Dudley","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biopsych.2013.11.019_bib22","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1523\/JNEUROSCI.4717-09.2010","article-title":"Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer\u2019s amyloid(beta)42 from isolated intact nerve terminals","volume":"30","author":"Kim","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2013.11.019_bib23","first-page":"S126","article-title":"WIP1104. Behavioral deficits in APP transgenic mice reversed by mGluR inhibitor with pro-neurogenic, A\u03b2-reducing, and anxiolytic properties [abstract]","volume":"72","author":"Gandy","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2013.11.019_bib24","doi-asserted-by":"crossref","first-page":"e60921","DOI":"10.1371\/journal.pone.0060921","article-title":"Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology","volume":"8","author":"Krabbe","year":"2013","journal-title":"PLoS One"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322313010317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322313010317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:57:57Z","timestamp":1757775477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322313010317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0006322313010317"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2013.11.019","relation":{},"ISSN":["0006-3223"],"issn-type":[{"type":"print","value":"0006-3223"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer\u2019s Disease: New Data Highlight Nonneuronal Cell Types and the Necessity for Presymptomatic Prevention Strategies","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2013.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}